Related Experiment Video
Updated: Aug 15, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Aberrantly expressed long noncoding RNAs and genes in Parkinson's disease
Yong Zhou1, Chengzhi Gu1, Jia Li1
1Department of Neurology, The Second Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, Nantong, China, huanghuaiyu99@163.com.
Neuropsychiatric Disease and Treatment
|December 13, 2018
Summary
This study identified key genes and long noncoding RNAs (lncRNAs) linked to Parkinson's disease (PD) pathogenesis. These findings offer new insights for developing potential PD biomarkers.
Area of Science:
- Neuroscience
- Genomics
- Molecular Biology
Background:
- Parkinson's disease (PD) is a prevalent neurodegenerative disorder with an unclear pathogenesis.
- Identifying key genetic and noncoding RNA players is crucial for understanding PD.
Purpose of the Study:
- To explore key genes and long noncoding RNAs (lncRNAs) associated with Parkinson's disease.
- To identify potential molecular targets for PD diagnosis and treatment.
Main Methods:
- RNA sequencing and bioinformatics analysis were performed on three PD patients and three healthy controls.
- Protein-protein interaction networks were constructed, and differentially expressed genes (DEGs) and lncRNAs (DELs) were identified.
- cis-acting regulatory elements and interactions between DEGs and DELs were analyzed, with validation using public datasets (GSE57475, GSE68719).
Main Results:
- A total of 857 differentially expressed messenger RNAs (DEmRNAs) and 77 differentially expressed long noncoding RNAs (DElncRNAs) were identified between PD patients and controls.
- Natural killer cell-mediated cytotoxicity was a significantly enriched pathway in PD.
- Key interactions between DElncRNAs and DEmRNAs, such as LOC105378701-TAL1 and LOC105375056-TREML1/TREML4, were identified, and hub proteins like ERBB2, HSPB1, and MYC were highlighted.
Conclusions:
- This study successfully identified critical genes and lncRNAs implicated in Parkinson's disease.
- The findings provide novel insights into PD pathogenesis and suggest potential biomarkers for early detection and therapeutic strategies.
More Related Videos
Related Concept Videos
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...